Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alnylam Pharmaceuticals
(NQ:
ALNY
)
153.68
+3.37 (+2.24%)
Streaming Delayed Price
Updated: 2:17 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
Next >
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
December 01, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
November 09, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
October 27, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
October 27, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
October 13, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
October 06, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
September 30, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces New Management Appointments
September 21, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
September 20, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
September 19, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
September 15, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
September 13, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
September 13, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
September 12, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
September 08, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
August 29, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
August 24, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
August 18, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
August 03, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
August 02, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
July 28, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
July 27, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
July 18, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
June 13, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
June 09, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
June 02, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
June 02, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
May 24, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
May 23, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.